The use of meperidine can lead to neuropsychiatric tox icity manifested by excitatory states and seizure. Nor meperidine, an active metabolite, is the agent responsi ble for this toxicity; its long half-life of elimination allows for significant accumulation with repeated dosing of the parent compound. Normeperidine is proconvul sant, and this property alone may account for the toxic symptoms. Psychiatric symptoms often herald the onset of toxicity and may be the result of complex partial seizure. A pathophysiological mechanism of toxicity is suggested, and management of the toxic patient is dis cussed.
Get full access to this article
View all access options for this article.
References
1.
Seitner PG, Martin BCSurvey of analgesic drug prescribing patterns. Washington, DC: The Drug Abuse Council, 1975 :6-7
2.
Andrews HLCortical effects of demerol. J Pharmacol Exp Ther1942;76:89-94
3.
Szeto HF, Inturrisi CE, Houde R., et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med1977;86:738-741
4.
Kaiko RF, Foley KM, Grabinski PYCentral nervous system excitatory effects of meperidine in cancer patients . Ann Neurol1983;13:180-185
5.
Miller RR, Jick H.Clinical effects of meperidine in hospitalized medical patients. J Clin Pharmacol1978;18:180-189
Folstein MF, Folstein SE, McHugh PRMini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975;12:189-198
8.
Deneau GA, Nakai K.The toxicity of meperidine in the monkey as influenced by its rate of absorption . Bulletin, Drug Addiction and Narcotics Appendix1961;6:2460-2469
9.
Yeh SYMetabolism of meperidine in several animal species. J Pharm Sci1984;73:1783-1787
10.
Stambaugh JE , Hemphill DM, Wainer IW, et al. A potentially toxic drug interaction between pethidine and phenobarbitone. Lancet1977;1:398-399
11.
Goetting MG , Thirman MJNeurotoxicity of meperidine. Ann Emerg Med1985;14:1007-1009
12.
Martin EWHazards of medication, 2nd edition. Philadelphia: Lippincott, 1978:529-530
13.
Vigran IMDangerous potentiation of meperidine hydrochloride by pargyline hydrochloride . JAMA1964;187:953-954
14.
Mitchell RSFatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med1955;42:417-424
15.
Pond SM, Kretschmar KMEffect of phenytoin on meperidine clearance and normeperidine formation. Clin Pharmacol Ther1981;30:680-686
16.
Miller JW, Anderson HHThe effect of N-demethylation on certain pharmacologic actions of morphine, codeine, and meperidine in the mouse. J Pharmacol Exp Ther1954; 112:191-196
17.
Umans JG, Inturrisi CEAntinociceptive activity and toxicity of meperidine and normeperidine in mice . J Pharmacol Exp Ther1982;223:203-206
18.
Cowan A., Geller EB, Adier MWClassification of opioids on the basis of change in seizure threshold in rats . Science1979;206:465-467
19.
Schomer DLPartial epilepsy. N Engl J Med1983;309:536-539
20.
Murray GBComplex partial seizures. In: Manschreck TC , ed. Psychiatric medicine update: Massachusetts General Hospital reviews for physicians. New York: Elsevier, 1981;103-118
21.
Daly DDIctal clinical manifestations of complex partial seizures. In: Penry JK, Daly DD, eds. Advances in neurology (Vol. II): complex partial seizures and their treatment. New York: Raven Press, 1975:57-84
22.
Post RM, Kopanda RT, Lee A.Progressive behavioral changes during chronic lidocaine administration: relationship to kindling. Life Sci1975;17:943-950
23.
Post RM, Kopanda RTCocaine, kindling and psychosis. Am J Psychiatry1976;133:627-634
24.
Post RMBehavioral effects of kindling. In: Parsonage M, Grant RHE, Craig AG, Wards AA, eds. Advances in epileptology: XIVth Epilepsy International Symposium . New York: Raven Press, 1983:173-180
25.
Goddard GV, McIntyre DC, Leech CK A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol1968;25:295-330
26.
Adamec RE, Stark-Adamec C.Limbic hyperfunction, limbic epilepsy, and interictal behavior: models and methods of detection. In: Doane BK, Livingston KE, eds. The limbic system: functional organization and clinical disorders. New York: Raven Press, 1986:129-145
27.
Winter CA, Flataker L.Effect of N-allylnormorphine upon massive doses of narcotic drugs. Proc Soc Exp Biol Med1956;93:158-160
28.
Shee JCDangerous potentiation of pethidine by iproniazid, and its treatment. Br Med J1960;2:507-509
29.
Meyer D., Halfin V.Toxicity secondary to ineperidine in patients on monoamine oxidase inhibitors: a case report and critical review. J Clin Psychopharmacol1981;1:319-321
30.
Browne B., Linter S.Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment. Br J Psychiatry1987;151:210-212
